Lorna

Lorna is a platform built to shift the center of gravity in investment analysis from earnings to cash flow. At its core is a proprietary metric called the Cash Flow Momentum Score (CFMS), which evaluates a company's financial health by tracking the trajectory of its cash flow generation. This is a deliberate departure from the earnings-centric models that dominate most screening tools, and for investors who recognize that cash flow often tells a truer story about a company's operational reality, Lorna offers a focused and potentially powerful lens. The platform covers more than 5,000 U.S. and Canadian companies, and its CFMS is updated daily, which means users are working with a near-real-time pulse on cash flow momentum rather than stale quarterly snapshots. Lorna claims a 99.9% accuracy rate for its CFMS system, a striking figure that demands scrutiny. Without independent validation, such a claim should be treated as a marketing assertion rather than a verified benchmark, but it does signal the confidence the company places in its underlying algorithm. The platform is designed to serve a range of users, from retail investors who want institutional-grade insights without the institutional price tag, to financial analysts who can use CFMS as a complementary layer alongside traditional metrics like P/E ratios or EBITDA. For investment managers and portfolio managers, Lorna's automated investing strategies and risk mitigation tools promise to streamline the screening process and flag companies with weakening cash flow before conventional indicators catch up. The AI-powered analysis and intelligent document analysis features aim to reduce the manual grind of parsing 10-Ks and quarterly reports, converting dense filings into digestible signals. However, Lorna's limitations are as notable as its strengths. The platform is restricted to North American markets, so investors with global portfolios will need to look elsewhere or use it only for their U.S. and Canadian holdings. Pricing details are conspicuously absent from publicly available information, which makes it difficult to assess whether the tool offers genuine value relative to its cost. The 'Freemium' label suggests a free tier exists, but the boundaries between free and paid features are unclear. For a retail investor, the decision to adopt Lorna hinges on whether cash flow momentum aligns with their investment philosophy. Value investors, in particular, may find CFMS a natural fit, while growth investors who prioritize revenue acceleration might find it less relevant. The automated investing strategies, while convenient, also carry the caveat that they may not adapt well to sudden market regime changes or idiosyncratic company events. Ultimately, Lorna is not a replacement for comprehensive due diligence, but a specialized tool that excels at one thing: quantifying cash flow health and momentum. For investors who believe cash flow is the bedrock of financial stability, and who operate within the North American market, Lorna is worth a serious look. For those who need global coverage, transparent pricing, or a broader analytical framework, it may be a piece of a larger puzzle rather than the whole solution.